FDA Approves New Obesity Drug Wegovy

• It has been able to do thrice what the other medications in the market for obesity can. 
• Wegovy has also not brought up any alarms in regards to the drug triggering bad side effects such as what the other treatments have caused patients.

Testimonial

Greenleaf is one of the patients who applied for the clinical trial of Welovy in 2018. This was after the 58-year-old had struggled with her weight for what seemed to be forever. She had tried all sorts of diets and was never able to lose any weight. The drug was administered by a weekly shot.

How does the drug work?

The drug takes direct action on the brain. This means that it will help people make sure that they eat less compared to their normal intake. This in turn is helpful in the excess weight being addressed as well as ensures the proper health and functioning of body parts such as the liver and the heart.

Insurance and obesity drugs

It has come to be known that insurance is not just tough on Wegrovy but all obesity drugs as a whole when it comes to their approval. There are only a handful of private insurers out there who cover drugs for obesity, Wegrovy still does not know where they stand in regards to the medication. The majority of the patients as well as the doctors have hope that all will go well in terms of the insurance agreeing to cover Wegrovy since it is an increased dose of Ozempic (a diabetic medication) that is often covered by insurance.

Considering Medicare does not give provision for obesity, most of the other private insurers subsequently do not because they follow what Medicare does. 

Why has FDA taken time in terms of approving obesity treatments?

The physicians at FDA have been very skeptical when it comes to approval of obesity medications because there have been several medications that had seemed promising to them, only for them to end up not only highly addictive but also be a cause of the problems that are related to one’s heart valve.

The pricing of Wegovy